# Summary statistics - quantitative results

## EQA round: RF1/23 - Diagnostics of Rheumatoid Arthritis and ASLO

Deadline: 17.3.2023

Setup: groups - manufacturer of kit; minimal size of the groups n = 5

| | |
|---|---|
| RoM = robust average | AV = assigned value |
| SD = standard deviation | CVPG = consensus of the participants' groups |
| CV = coefficient of variation | $U_{AV}$ = expanded uncertainty of the assigned value (k = 2) |
| $N_{tot}$ = total number of the results | |
| $N_{out}$ = number of the results removed before calculation | |

| | |
|---|---|
| $D_{max}$ = acceptable difference | |
| LL = lower limit | |
| UL = upper limit | |
| $N_{eva}$ = number of the results assessed | |
| $N_{suc}$ = number of successful results | |
| $S_{rel}$ = relative success | |

| Test Sample Group | [unit] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **(237) anti-streptolysin O (ASLO)** | [kU/L] | | | | 167 | | | | | | | | 148 | 141 | 95 |
| **Sample A2** | | 309 | 63 | 20 | 167 | | | | | | | | 148 | 145 | 98 |
| (1) Abbott | | 228 | 6,7 | 2,9 | 42 | 0 | CVPG | 228 | 2,5 | 20% | 182 | 274 | 42 | | |
| (58) Beckman Coulter (AU) | | 319 | 18 | 5,6 | 30 | 0 | CVPG | 319 | 8 | 20% | 255 | 383 | 30 | | |
| (60) Roche | | 345 | 16 | 4,7 | 46 | 0 | CVPG | 345 | 5,8 | 20% | 276 | 414 | 46 | | |
| (149) Siemens (Dade, BN, Dimension) | | 330 | 16 | 4,7 | 9 | 0 | CVPG | 330 | 19 | 20% | 264 | 396 | 9 | | |
| (162) Siemens (Atellica) | | 371 | 15 | 4,1 | 13 | 0 | CVPG | 371 | 10 | 20% | 296 | 446 | 13 | | |
| (179) Siemens | | 371 | 24 | 6,4 | 8 | 0 | CVPG | 371 | 18 | 20% | 296 | 446 | 8 | | |
| Other | | | | | 19 | 0 | | | | | | | 0 | | |
| 4x 12, 3x 91, 3x 115, 1x 116, 4x 177, 3x 178, 1x 999 | | | | | | | | | | | | | | | |
| **Sample B2** | | 77 | 13 | 17 | 167 | | | | | | | | 148 | 142 | 96 |
| (1) Abbott | | 61,5 | 3,7 | 6 | 42 | 0 | CVPG | 61,5 | 1,4 | 20% | 49,2 | 73,8 | 42 | | |
| (58) Beckman Coulter (AU) | | 79,3 | 8,1 | 10 | 30 | 0 | CVPG | 79,3 | 3,6 | 20% | 63,4 | 95,2 | 30 | | |
| (60) Roche | | 82,4 | 7,1 | 8,6 | 46 | 0 | CVPG | 82,4 | 2,6 | 20% | 65,9 | 98,9 | 46 | | |
| (149) Siemens (Dade, BN, Dimension) | | 88 | 4,4 | 5,1 | 9 | 0 | CVPG | 88 | 5,5 | 20% | 70,4 | 106 | 9 | | |
| (162) Siemens (Atellica) | | 83,5 | 5,4 | 6,4 | 13 | 0 | CVPG | 83,5 | 3,7 | 20% | 66,8 | 101 | 13 | | |
| (179) Siemens | | 86,5 | 2,2 | 2,6 | 8 | 0 | CVPG | 86,5 | 1,7 | 20% | 69,2 | 104 | 8 | | |
| Other | | | | | 19 | 0 | | | | | | | 0 | | |
| 4x 12, 3x 91, 3x 115, 1x 116, 4x 177, 3x 178, 1x 999 | | | | | | | | | | | | | | | |